Bayer Zydus Pharma Private Limited, a active private limited company, was established on 07 February 2011 in Thane, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24233MH2011PTC213118. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹100.00 Cr and a paid-up capital of ₹50.00 Cr.
It upholds a compliant status. Employing 713 professional, Its leadership includes Shweta Rai (Managing Director), Sunil Prakashlal Narwani (Additional Director). Past directors included Manoj Kumar Satish Saxena, Ganesh Narayan Nayak, Atul Kumar Samalia. Its latest AGM occurred on 13 September 2024, with the balance sheet filed on 31 March 2024. It is based at Bayer House, Central Avenue, Hiranandani Estate, Thane (West), Thane, Maharashtra, 400607.
U24233MH2011PTC213118
213118
07 February 2011
₹100.00 Cr
₹50.00 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Bayer Zydus Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shweta Rai | Managing Director | 14 Dec 2023 | Current |
| Sunil Prakashlal Narwani | Additional Director | 26 May 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 01 Apr 2017 | Past |
| Pramod Abcsdd | Additional Director | 31 May 2012 | Past |
| Pramod Abcsdd | Director | 28 Feb 2011 | Past |
| Pramod Abcsdd | Director | 10 Apr 2013 | Past |
| Pramod Abcsdd | Additional Director | 03 May 2024 | Past |
| Pramod Abcsdd | Additional Director | 31 May 2012 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bayer Zydus Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.76% decrease. The company also saw a substantial improvement in profitability, with a 232.18% increase in profit. The company's net worth Soared by an impressive increase of 14.94%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Bayer Zydus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Bayer Zydus Pharma has a workforce of 713 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Bayer Zydus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bayer Zydus Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Anup Pramodkumar Hebsur was appointed as a Company Secretary was appointed as a Company Secretary on 25 Jun 2025 & has been associated with this company since 5 months 9 days . was completed.
Progress on Sunil Prakashlal Narwani was appointed as a Additional Director was appointed as a Additional Director on 26 May 2025 & has been associated with this company since 6 months 9 days . was documented.
Bayer Zydus Pharma Private Limited last Annual general meeting of members was held on 13 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Bayer Zydus Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was documented.
Shweta Rai was appointed as a Managing Director was appointed as a Managing Director on 14 Dec 2023 & has been associated with this company since 1 year 11 months . was recorded as a recent event.
The activity Bayer Zydus Pharma Private Limited was registered on 07 Feb 2011 with Roc Mumbai & aged 14 years 9 months as per MCA records. was completed.
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025..
Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients. .
Bayer raised the objection against Natcos brand launched under the name Regonat alleging infringement of its patent rights..
The CIN of Bayer Zydus Pharma Private Limited is U24233MH2011PTC213118.
Bayer Zydus Pharma Private Limited is headquartered at Bayer House, Central Avenue, Hiranandani Estate, Thane (West), Thane, Maharashtra, 400607.
Bayer Zydus Pharma Private Limited was incorporated on 07 February 2011.
The current directors of Bayer Zydus Pharma Private Limited are
The primary industry of Bayer Zydus Pharma Private Limited is Trade.
Bayer Zydus Pharma Private Limited is unlisted.
The authorized capital of Bayer Zydus Pharma Private Limited is ₹100.00 Cr, and the paid-up capital is ₹50.00 Cr.
The compliance status of Bayer Zydus Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX